Can you buy NextPoint Therapeutics stock?

As NextPoint Therapeutics is not publicly traded, purchasing its stock is not available to everyone. To buy the stock of a private company likeNextPoint Therapeutics, you must be an accredited investor . If you meet the accreditation criteria, you can register for Forge’s Secondary Marketplace to buy private market stock. If you are not an accredited investor, discover how to begin the process to potentially qualify for new investment opportunities.

How to buy NextPoint Therapeutics stock?

To invest in a private company like NextPoint Therapeutics through Forge, you must first qualify as an accredited investor. (Learn more about the accreditation process . 1. Create a free account to access Forge’s marketplace. 2. Express your interest in specific investments. Within Forge Markets, you will find detailed pricing and financing information for thousands of private companies. 3. Throughout this process, a dedicated Forge Private Market Specialist will be available to address any questions you may have and to guide you seamlessly through each step of the transaction.

Can you sell NextPoint Therapeutics stock?

Yes, you may be able to sell your NextPoint Therapeutics stock, subject to certain conditions. Forge can help you facilitate the sale of your stock in a manner that aligns with your needs and the company’s interests. If you are looking for liquidity, register with us today to begin the process. A dedicated Forge Private Market Specialist will be available to address any questions you may have along the way.

How to sell NextPoint Therapeutics stock?

If you hold private company shares of NextPoint Therapeutics - whether as an employee or an early investor - Forge can help you sell them. 1. Create a free Forge account, this will give you access to Forge’s marketplace and to one of our experienced Private Market Specialist to answer any questions you might have. 2. Indicate your interest to sell your NextPoint Therapeutics stock on our platform. 3. Work with your dedicated Private Market Specialist who’ll help guide you through every step of the transaction.

Is NextPoint Therapeutics a public company?

No, NextPoint Therapeutics is a privately held company and is currently not publicly traded on any stock markets including NYSE or NASDAQ.

What is NextPoint Therapeutics’ stock price?

NextPoint Therapeutics is a privately held company and therefore does not have a public stock price. However, you may access NextPoint Therapeutics’ private market stock price with Forge Data .

What is NextPoint Therapeutics’ stock ticker symbol?

NextPoint Therapeutics does not have an official ticker symbol because this company is not currently publicly traded.

Can institutional investors buy and sell private market stocks?

Yes. As one of the largest trading platform for the private market, Forge helps institutional investors seek liquidity as they buy and sell private stock for their portfolios or their clients. Our private market specialists have decades of experience working with institutional firms. Learn more or register today to get started.

Invest and Sell NextPoint Therapeutics Stock

FINSMES 02/15/2024

NextPoint Therapeutics Raises $42.5M; Closes $122.5M Series B Financing

NexPoint raised $122.5 million in a recent series B funding round to continue developing their oncology drugs.

BioSpace 02/14/2024

NextPoint Therapeutics Announces Closing of Series B Financing Extension Led by Catalio Capital Management

NextPoint Therapeutics, a clinical-stage biotechnology company developing a new class of precision oncology therapeutics targeting the novel HHLA2 pathway, announced today the closing of a $42.5M Extension to its Series B financing round resulting in a total of $122.5M raised in the Series B financing. The funds will be used to advance the company’s two immuno-oncology clinical programs, NPX267 and NPX887, as well as propel the development of additional therapeutic modalities in the pipeline that target the novel HHLA2 tumor antigen.

Business Wire 01/24/2023

NextPoint Therapeutics Announces $80 Million Series B Financing co-led by Leaps by Bayer and Sanofi Ventures to Advance Novel Immuno-Oncology Programs

Programs target the novel HHLA2 pathway, activating anti-tumor immune responses to find and destroy cancer cells

NextPoint Therapeutics Stock

Register To Buy and Sell Shares

Enterprise Value

Access NextPoint Therapeutics’ valuation and stock price.

NextPoint Therapeutics investors also invested in these private companies

Team

Management Team

Board Members

NextPoint Therapeutics stock FAQs